Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1627029 | 0.93 | NPSR1 (0.43) | SLC6A2SLC6A4SLC6A3NPSR1PTK2 | |
| SCHEMBL5017049 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPT | |
| SCHEMBL18354246 | 0.74 | PIK3C3 (0.36) | SLC6A2SLC6A4SLC6A3PTK2ALDH1A1 | |
| SCHEMBL13345042 | 0.74 | NPSR1 (0.44) | SLC6A2SLC6A4SLC6A3NPSR1ALDH1A1 | |
| SCHEMBL1371755 | 0.74 | NPSR1 (0.44) | SLC6A2SLC6A4SLC6A3NPSR1ALDH1A1 | |
| SCHEMBL1163552 | 0.73 | PTK2 (0.40) | SLC6A2SLC6A4SLC6A3NPSR1PTK2 | |
| SCHEMBL12409789 | 0.73 | CYP19A1 (0.40) | NPSR1PTK2ALDH1A1 | |
| SCHEMBL955246 | 0.73 | PSIP1 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL17258854 | 0.72 | PTK2 (0.40) | NPSR1PTK2ALDH1A1 | |
| SCHEMBL18559539 | 0.72 | LMNA (0.42) | ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20160130250-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130250-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2016-05-12 | — | — | US | disclosed |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8440822-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. | 2013-05-14 | — | — | US | disclosed |
| US-8440822-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. | 2013-05-14 | — | — | US | disclosed |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER, INC. | 2013-01-03 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
| US-20160130250-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | SLC6A2 3076/4885SLC6A4 2785/4885SLC6A3 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.